Type 1 diabetes is a chronic condition in which the immune system destroys the cells in the pancreas that produce insulin. Without insulin, your body can’t move sugar from the bloodstream into cells for energy, so blood sugar rises to dangerous levels. It accounts for roughly 5 to 10 percent of all diabetes cases and requires lifelong insulin replacement.
What Happens Inside the Body
Insulin is made by beta cells, which live in small clusters called islets scattered throughout the pancreas. In type 1 diabetes, white blood cells mistakenly identify these beta cells as foreign and begin attacking them. The process is surprisingly subtle: fewer than 10 percent of islets become infiltrated, and each infiltrated islet may contain only about 15 immune cells. Yet over months or years, that low-level assault steadily whittles down the beta cell population.
Symptoms don’t appear the moment the immune attack starts. Based on surgical data, at least 50 percent of beta cells need to be destroyed before blood sugar rises enough to cause noticeable problems. This means the disease can be silently progressing long before anyone feels anything wrong. By the time symptoms show up, the pancreas has already lost a significant portion of its insulin-producing capacity.
Who Gets It and Why
Type 1 diabetes can appear at any age, though it’s most commonly diagnosed in children, teens, and young adults. Genetics play a role: having a parent or sibling with the condition increases your risk. But genes alone aren’t enough. Something in the environment, possibly a viral infection, appears to trigger the immune system to turn against beta cells in genetically susceptible people. The exact trigger remains unclear, and most people diagnosed have no family history at all.
The American Diabetes Association now recommends autoantibody-based screening for people with a family history of type 1 diabetes or known genetic risk markers. A simple blood test can detect immune antibodies that signal the attack on beta cells has begun, sometimes years before symptoms develop. Early detection opens a window for monitoring and, in some cases, treatments that can delay the onset of full-blown disease.
Symptoms and How They Appear
Unlike type 2 diabetes, which tends to creep in gradually, type 1 symptoms often arrive suddenly. The classic signs include:
- Intense thirst and frequent urination
- Unexplained weight loss despite feeling very hungry
- Fatigue and weakness
- Blurry vision
- Irritability or mood changes
- Bed-wetting in children who previously stayed dry at night
These symptoms develop because, without enough insulin, sugar accumulates in the blood instead of entering cells. The kidneys work overtime to filter out the excess sugar, pulling water along with it, which explains the constant thirst and urination. Meanwhile, cells starved for fuel start breaking down fat and muscle for energy, causing weight loss even when appetite increases.
Diabetic Ketoacidosis: The Emergency to Know About
When the body breaks down fat for energy at a rapid pace, it produces acidic byproducts called ketones. If ketones build up faster than the body can clear them, the blood becomes dangerously acidic. This condition, called diabetic ketoacidosis (DKA), is a medical emergency and is sometimes the event that leads to a type 1 diagnosis in the first place.
Early warning signs include extreme thirst, frequent urination, and high blood sugar (above 250 mg/dL). As it progresses, symptoms escalate to nausea, vomiting, abdominal pain, rapid deep breathing, fruity-smelling breath, confusion, and eventually loss of consciousness. DKA is diagnosed when blood pH drops below 7.3 and ketones are present in the blood or urine. It can also occur at blood sugar levels below 250 mg/dL, a less recognized form called euglycemic DKA, which makes it important to check for ketones whenever you feel unwell.
How Type 1 Differs From Type 2
Both types involve high blood sugar, but the underlying problem is fundamentally different. In type 1, the pancreas produces little to no insulin because the beta cells have been destroyed. In type 2, the pancreas still makes insulin, but the body’s cells don’t respond to it efficiently, a problem called insulin resistance. Over time, the pancreas in type 2 may also lose some capacity, but the starting point is resistance rather than destruction.
A blood test measuring C-peptide helps distinguish between the two. C-peptide is released alongside insulin in equal amounts, so its level reflects how much insulin your pancreas is actually producing. In type 1, C-peptide is low because few beta cells remain. In type 2, C-peptide is typically normal or even high, reflecting the body’s attempt to overcome resistance by pumping out more insulin. Because C-peptide isn’t affected by injected insulin, it gives an accurate picture of natural production regardless of treatment.
The Honeymoon Phase
Shortly after diagnosis and the start of insulin therapy, many people experience a period of surprisingly easy blood sugar control. This “honeymoon phase” happens because the remaining beta cells, relieved of the extreme stress of uncontrolled high blood sugar, temporarily recover some function. During this window, the pancreas still produces a meaningful amount of insulin, which reduces the dose of external insulin needed.
The honeymoon phase varies enormously from person to person. Remission rates in studies range from 25 to 100 percent of newly diagnosed patients, and the duration can last anywhere from one month to as long as 13 years. It always ends eventually as the immune system continues its attack, but it can create confusion for newly diagnosed patients who wonder whether the diagnosis was wrong. It wasn’t. The underlying autoimmune process is still active.
Daily Management
Everyone with type 1 diabetes needs external insulin, delivered either through multiple daily injections or an insulin pump worn on the body. There’s no pill form of insulin because stomach acid destroys it before it can reach the bloodstream. Management revolves around matching insulin doses to food intake, physical activity, stress, and illness, a constant balancing act that requires attention throughout the day.
Continuous glucose monitors (CGMs) have transformed daily management by providing real-time blood sugar readings every few minutes through a small sensor worn under the skin. The latest step forward is hybrid closed-loop systems, sometimes called artificial pancreas technology. These systems pair a CGM with an insulin pump and a computer algorithm that automatically adjusts background insulin delivery based on current and predicted blood sugar levels. They can also deliver small correction doses between meals. Clinical data shows these systems increase the time blood sugar stays in the target range by up to 10 percent overall and 15 percent overnight compared to older pump technology. Meals still require manual input, since you need to estimate carbohydrates and tell the system to deliver a bolus, but the automation handles much of the fine-tuning.
Long-Term Complications
Chronic high blood sugar damages blood vessels over time, and the consequences show up in two broad categories. Small-vessel damage (microvascular disease) affects the eyes, kidneys, and nerves. Retinopathy, or damage to the blood vessels in the retina, is extremely common, appearing in 82 to 100 percent of people with long-standing type 1 diabetes. Kidney disease develops in 20 to 40 percent, and nerve damage (neuropathy) in 23 to 29 percent, causing numbness, tingling, or pain most often in the feet and hands.
Large-vessel damage (macrovascular disease) raises the risk of heart disease, stroke, and poor circulation in the legs. These risks begin earlier in life for people with type 1 diabetes compared to the general population. The good news: decades of research show that keeping blood sugar closer to the normal range significantly reduces the risk and severity of all these complications. Modern tools like CGMs and closed-loop systems make tighter control more achievable than it was even a decade ago.
Getting Diagnosed
Diabetes is confirmed when blood sugar exceeds specific thresholds. The American Diabetes Association’s current diagnostic criteria include an A1C of 6.5 percent or higher, a fasting blood sugar of 126 mg/dL or above, or a two-hour blood sugar of 200 mg/dL or above after a glucose tolerance test. Without obvious high blood sugar symptoms, two abnormal results are needed, either from different tests at the same time or the same test repeated on a separate day.
Once diabetes is confirmed, additional tests help determine whether it’s type 1. Autoantibody blood tests detect the immune markers specific to the attack on beta cells, and a low C-peptide level confirms that insulin production is severely reduced. These distinctions matter because treatment is different: type 1 always requires insulin from the start, while type 2 may initially be managed with lifestyle changes and oral medications.